GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fennec Pharmaceuticals Inc (TSX:FRX) » Definitions » Net Interest Income (for Banks)

Fennec Pharmaceuticals (TSX:FRX) Net Interest Income (for Banks)


View and export this data going back to 2001. Start your Free Trial

What is Fennec Pharmaceuticals Net Interest Income (for Banks)?

Net Interest Income only applies to banks.


Fennec Pharmaceuticals (TSX:FRX) Business Description

Traded in Other Exchanges
Address
68 TW Alexander Drive, PO Box 13628, Research Triangle Park, NC, USA, 27709
Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children. The company principally operates in the United States.